SLL-023ACP, a KOR/MOR dual agonist, produces potent antinociception with fewer side effects

Key Points

• SLL-023ACP produces potent antinociception with a significant reduction in side effects related to opioids.
• In tests, SLL-023ACP showed a notable improvement in pain relief compared to traditional opioid agonists.
• The study utilized pharmacological assessments to evaluate both efficacy and safety of SLL-023ACP in pain models.
• This dual agonist approach may enhance pain management while minimizing the risks typically associated with opioid therapies.